Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.75 BRL | +0.27% |
|
-2.29% | -27.91% |
Strengths
- With a P/E ratio at 10.04 for the current year and 9.03 for next year, earnings multiples are highly attractive compared with competitors.
- The company is one of the best yield companies with high dividend expectations.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-27.91% | 185M | - | ||
+4.74% | 40.94B | A- | ||
-11.48% | 33.35B | B- | ||
+82.19% | 29.53B | A | ||
-13.94% | 15.76B | C | ||
-3.33% | 13.65B | B- | ||
-12.64% | 11.44B | D+ | ||
+166.50% | 10.08B | D | ||
+5.02% | 9.06B | B+ | ||
-57.32% | 8.58B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- OFSA3 Stock
- Ratings Ouro Fino Saúde Animal Participações S.A.